LUNG · Company research
Pulmonx Corporation Common Stock (LUNG): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| JPMorgan cuts Hang Lung stock target to HKD 6.60 from HKD 10.00 - ad-hoc-news.de | JPMorgan cuts Hang Lung stock target to HKD 6.60 from HKD 10.00 ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 17, 2026 | neutral | 0 | 0.6 |
| PFE Stock Continues To Drop As Lung Cancer Trial Disappointment Overshadows Ibrance Win - Stocktwits | PFE Stock Continues To Drop As Lung Cancer Trial Disappointment Overshadows Ibrance Win Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| BMY Stock Drops As Lower-Dose Lung Drug Succeeds In Trial, Higher Dose Misses - Yahoo Finance | BMY Stock Drops As Lower-Dose Lung Drug Succeeds In Trial, Higher Dose Misses Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’ - Stocktwits | AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’ Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| Pulmonx (LUNG) Slips 2.45% to $1.79 as Shares Approach Key Support - Institutional Flow Picks - https://www.siam.in/ | Pulmonx (LUNG) Slips 2.45% to $1.79 as Shares Approach Key Support - Institutional Flow Picks https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 8, 2026 | neutral | 0 | 0.6 |
| BIAF Stock Draws Traders As CyPath Lung Growth Accelerates - StocksToTrade | BIAF Stock Draws Traders As CyPath Lung Growth Accelerates StocksToTrade | View source ↗ | StocksToTrade | Oct 8, 2026 | neutral | 0 | 0.6 |
| BIAF Stock Draws Traders As CyPath Lung Growth Accelerates - Timothy Sykes | BIAF Stock Draws Traders As CyPath Lung Growth Accelerates Timothy Sykes | View source ↗ | Timothy Sykes | Oct 8, 2026 | neutral | 0 | 0.6 |
| SMMT Stock Gains After Summit Reports Strong Lung Cancer Survival Results — Investors Await Q2 Earnings - Stocktwits | SMMT Stock Gains After Summit Reports Strong Lung Cancer Survival Results — Investors Await Q2 Earnings Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| Hang Lung stock sits near its 52-week low at HKD 6.60 - AD HOC NEWS | Hang Lung stock sits near its 52-week low at HKD 6.60 AD HOC NEWS | View source ↗ | AD HOC NEWS | Oct 8, 2026 | neutral | 0 | 0.6 |
| Why Is ArriVent BioPharma Stock Tumbling Today? - ArriVent BioPharma (NASDAQ:AVBP) - Benzinga | Why Is ArriVent BioPharma Stock Tumbling Today? - ArriVent BioPharma (NASDAQ:AVBP) Benzinga | View source ↗ | Benzinga | Oct 6, 2026 | neutral | 0 | 0.6 |
| ArriVent’s phase 3 lung cancer trial flops, sinking stock - Fierce Biotech | ArriVent’s phase 3 lung cancer trial flops, sinking stock Fierce Biotech | View source ↗ | Fierce Biotech | Oct 6, 2026 | neutral | 0 | 0.6 |
| Hang Lung Properties (SEHK:101) Stock May Be Above Fair Value On Earnings - Yahoo Finance | Hang Lung Properties (SEHK:101) Stock May Be Above Fair Value On Earnings Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
| Merck withdrew its lung cancer drug application. A phase 3 trial is still enrolling. - Stock Titan | Merck withdrew its lung cancer drug application. A phase 3 trial is still enrolling. Stock Titan | View source ↗ | Stock Titan | Sep 25, 2026 | neutral | 0 | 0.6 |
| Taking Stock of Systemic and Local Therapy Trends in Lung Cancer With Drs Crowley and Moghanaki - OncLive | Taking Stock of Systemic and Local Therapy Trends in Lung Cancer With Drs Crowley and Moghanaki OncLive | View source ↗ | OncLive | Sep 17, 2026 | neutral | 0 | 0.6 |
| What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now? - Yahoo Finance | What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 14, 2026 | neutral | 0 | 0.6 |
| Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance | Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 3, 2026 | neutral | 0 | 0.6 |
| $LUNG stock is up 38% today. Here's what we see in our data. | LUNG Stock News - Quiver Quantitative | $LUNG stock is up 38% today. Here's what we see in our data. | LUNG Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 30, 2026 | neutral | 0 | 0.6 |
| Merck Stock Rises 6% as Lung Cancer Treatment Cuts Tumor Progression Risk Significantly - TIKR.com | Merck Stock Rises 6% as Lung Cancer Treatment Cuts Tumor Progression Risk Significantly TIKR.com | View source ↗ | TIKR.com | May 24, 2026 | neutral | 0 | 0.6 |
| Pulmonx Corporation (LUNG) Stock Falls on Q1 2026 Earnings - Quiver Quantitative | Pulmonx Corporation (LUNG) Stock Falls on Q1 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Apr 29, 2026 | neutral | 0 | 0.6 |
| AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed - CNBC | AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed CNBC | View source ↗ | CNBC | Mar 27, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.